Tau,Phospho-Tau,and S-100B in the Cerebrospinal Fluid of Children With Multiple Sclerosis

Abstract

Axonal injury and glial activation are an early neuropathologic event in adults with multiple sclerosis. To investigate whether markers of axonal injury and glial activation are already elevated in the cerebrospinal fluid of children with multiple sclerosis, we studied the cerebrospinal fluid of 25 children with multiple sclerosis and 67 controls for the presence of tau, phospho-tau, and S-100B proteins using specific enzyme-linked immunoabsorbent assays. In general, tau, phospho-tau, and S-100B protein levels did not differ significantly between groups. However, in a subgroup of nine children with multiple sclerosis, all of whom had prominent clinical symptoms at the time of lumbar puncture and radiologic disease activity, tau protein levels were significantly elevated when compared with other controls. These data indicate that axonal injury is not restricted to adult multiple sclerosis but can already occur in children with multiple sclerosis. ( J Child Neurol 2005;20:822—825).

Get full access to this article

View all access options for this article.

References

Duquette P. , Murray TJ , Pleines J. , et al: Multiple sclerosis in childhood: Clinical profile in 125 patients . J Pediatr 1987;111:359—363.

Bitsch A. , Schuchardt J. , Bunkowski S. , et al: Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000 ; 123:1174-1183.

Mandelkow E. , Mandelkow EM : Microtubules and microtubuleassociated proteins . Curr Opin Cell Biol 1995;7:72—81.

Kapaki E. , Paraskevas GP , Michalopoulou M. , Kilidireas K. : Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000;43:228—232.

Sussmuth SD , Reiber H. , Tumani H. : Tau protein in cerebrospinal fluid (CSF): A blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001;300:95—98.

Petzold A. , Eikelenboom MJ , Gveric D. , et al: Markers for different glial cell responses in multiple sclerosis: Clinical and pathological correlations. Brain 2002;125:1462—1473.

McDonald WI , Compston A. , Edan G. , et al: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121—127.

Otto M. , Wiltfang J. , Cepek L. , et al: Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002 ;58:192—197.

Vanmechelen E. , Vanderstichele H. , Davidsson P. , et al: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49—52.

10.

Otto M. , Wiltfang J. , Schuetz E. , et al: Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: Prospective case-control study. BMJ 1998;316:577—582.

11.

Hulstaert F. , Blennow K. , Ivanoiu A. , et al: Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555—1562.

12.

Jimenez-Jimenez FJ , Zurdo JM , Hernanz A. , et al: Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002;106:351—354.

13.

MikaeloffY, Moreau T , Debouverie M. , et al: Interferon-beta treatment in patients with childhood onset multiple sclerosis. J Pediatr 2001;139:443—446.